DLX-212

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDLX-212
Drug Alias Nameanti-beta amyloid antibody fragment (Delenex)anti-beta amyloid antibody fragment (Delenex)DLX-212
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCell Medica Switzerland AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCell Medica Switzerland AG
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A